Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease
Jessica Kendrick,Alfred K Cheung,James S Kaufman,Tom Greene,William L Roberts,Gerard Smits,Michel Chonchol,HOST (Homocysteinemia in Kidney and End Stage Renal Disease) Study Investigators,E Young,K Belanger,R Lopez,N Grunsten,P Sanders,D Killian,N Shanklin,J Kaufman,E Dibbs,E Langhoff,D Tyrrell,S Crowley,A Peixoto,A DeLorenzo,C Joncas,R T Miller,K Kaelin,M Markulin,D Dev,D Coussirat,A Sajgure,M Saklayen,H Neff,S Shook,M Chonchol,M Levi,L Clegg,A Singleton,D Abu-Hamdan,L Bey-Knight,K King,E Jones,C Palant,H Sheriff,C Simmons,J Sinks,C Wingo,B McAllister,J Sallustio,N Smith,S Popli,P Linnerud,A Zuluaga,G Dolson,G Tasby,R Agarwal,R Lewis,D Jasinski,N Sachs,D Veneck,S Ur Rehman,A Basu,K Ingram,R Paul,J Raymond,K Holmes,T Wiegmann,J Abdallah,A Nagaria,D Smith,A Renft,T Finnigan,G Feldman,S Schmid,C Cooke,B Wall,R Patterson,G Contreras,E Jaimes,G O'Brien,K Ma,J Rust,S Otterness,V Batuman,C Kulivan,D S Goldfarb,M Shea,F Modersitzki,T Dixon,E Pastoriza,L Titus,R Jamison,I Cook,M Anderson,P Palevsky,P Salai,S Anderson,J Walczyk,A Lindner,C Stehman-Breen,E Pascual,J Nugent-Carney,S Thomson,S Mullaney,J Dingsdale,C Rosado,C Azcona-Vilchez,S Betcher,C Rewakowski,D Cohen,G Flanagin,J Steffe,J Lohr,N Fucile,L Yohe,S Blumenthal,D Schmidt
DOI: https://doi.org/10.1053/j.ajkd.2012.04.014
Abstract:Background: Low vitamin D concentrations are prevalent in patients with chronic kidney disease (CKD). We investigated the relationship between plasma 25-hydroxyvitamin D (25[OH]D) or 1,25-dihydroxyvitamin D (1,25[OH](2)D) concentrations with death, cardiovascular events, and dialysis therapy initiation in patients with advanced CKD. Study design: The HOST (Homocysteinemia in Kidney and End Stage Renal Disease) Study was a randomized double-blind trial evaluating the effects of high doses of folic acid on death and long-term dialysis therapy initiation in patients with advanced CKD (stages 4 and 5 not yet on dialysis therapy). 25(OH)D and 1,25(OH)(2)D were measured in stored plasma samples obtained 3 months after trial initiation and evaluated at clinically defined cutoffs (<10, 10-30, and >30 ng/mL) and tertiles (<15, 15-22, and >22 pg/mL), respectively. Cox proportional hazard models were used to examine the association between vitamin D concentrations and clinical outcomes. Setting & participants: 1,099 patients with advanced CKD from 36 Veteran Affairs Medical Centers. Predictors: 25(OH)D and 1,25(OH)(2)D concentrations. Outcomes: Death, cardiovascular events, and time to initiation of long-term dialysis therapy. Results: After a median follow-up of 2.9 years, 41% (n = 453) died, whereas 56% (n = 615) initiated dialysis therapy. Mean 25(OH)D and 1,25(OH)(2)D concentrations were 21 ± 10 ng/mL and 20 ± 11 pg/mL, respectively. After adjustment for potential confounders, the lowest tertile of 1,25(OH)(2)D was associated with death (HR, 1.33; 95% CI, 1.01-1.74) and initiation of long-term dialysis therapy (HR, 1.78; 95% CI, 1.40-2.26) compared with the highest tertile. The association with death and initiation of dialysis therapy was moderately attenuated after adjustment for plasma fibroblast growth factor 23 (FGF-23) concentrations (HRs of lower tertiles of 1.20 [95% CI, 0.91-1.58] and 1.56 [95% CI, 1.23-1.99], respectively, compared with highest tertile). There was no association between 25(OH)D concentrations and outcomes. Limitations: Participants were mostly men. Conclusions: Low plasma 1,25(OH)(2)D concentrations are associated with death and initiation of long-term dialysis therapy in patients with advanced CKD. FGF-23 level may attentuate this relationship.